EA201991835A1 - 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamides for the treatment of malignant neoplasms - Google Patents

2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamides for the treatment of malignant neoplasms

Info

Publication number
EA201991835A1
EA201991835A1 EA201991835A EA201991835A EA201991835A1 EA 201991835 A1 EA201991835 A1 EA 201991835A1 EA 201991835 A EA201991835 A EA 201991835A EA 201991835 A EA201991835 A EA 201991835A EA 201991835 A1 EA201991835 A1 EA 201991835A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
heteroaryl
oxo
treatment
dihydropyridazin
Prior art date
Application number
EA201991835A
Other languages
Russian (ru)
Other versions
EA037978B1 (en
Inventor
Илона Гутхер
Ульрике Рён
Норберт Шмес
Людвиг Цорн
Ларс Рёзе
Беньямин Бадер
Кристина Кобер
Рафаэль Карретеро
Детлеф Штёккигт
Хорст Ирльбахер
Михаэль Платтен
Original Assignee
Байер Акциенгезельшафт
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт, Байер Фарма Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Priority claimed from PCT/EP2018/052627 external-priority patent/WO2018146010A1/en
Publication of EA201991835A1 publication Critical patent/EA201991835A1/en
Publication of EA037978B1 publication Critical patent/EA037978B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение охватывает 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамидные соединения общей формулы (I)в которой X, R, R, R, Rи Rявляются такими, как определено в настоящей заявке, способы получения указанных соединений, промежуточные соединения, пригодные для получения указанных соединений, фармацевтические композиции и комбинации, содержащие указанные соединения, и применение указанных соединений для производства фармацевтических композиций для лечения или профилактики заболеваний, в частности злокачественного новообразования или состояний с разрегулированными иммунными ответами, или других нарушений, связанных с аберрантной сигнализацией AHR, в виде единственного средства или в комбинации с другими активными компонентами.The present invention encompasses 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I) in which X, R, R, R, R and R are as defined in this application, processes for the preparation of said compounds , intermediates suitable for the preparation of said compounds, pharmaceutical compositions and combinations containing said compounds, and the use of said compounds for the production of pharmaceutical compositions for the treatment or prevention of diseases, in particular cancer or conditions with dysregulated immune responses, or other disorders associated with aberrant AHR signaling, alone or in combination with other active ingredients.

EA201991835A 2017-11-21 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer EA037978B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17202882 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (2)

Publication Number Publication Date
EA201991835A1 true EA201991835A1 (en) 2020-02-03
EA037978B1 EA037978B1 (en) 2021-06-18

Family

ID=60421681

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991835A EA037978B1 (en) 2017-11-21 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Country Status (2)

Country Link
EA (1) EA037978B1 (en)
PT (1) PT3580211T (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756275B2 (en) * 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
CA2673299C (en) * 2006-12-21 2016-04-12 Sloan-Kettering Institute For Cancer Research Pyridazinone compounds for the treatment of proliferative diseases
WO2017202816A1 (en) * 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides

Also Published As

Publication number Publication date
EA037978B1 (en) 2021-06-18
PT3580211T (en) 2021-02-01

Similar Documents

Publication Publication Date Title
EA201892666A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydro-pyridazine-4-carboxamides
PH12019501846A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PH12018501877A1 (en) Substituted indole mcl-1 inhibitors
EA201790492A1 (en) CONNECTIONS THAT INHIBIT McL-1 PROTEIN
MX2023005636A (en) Benzimidazolone derived inhibitors of bcl6.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA202090448A1 (en) Dihydrooxadiazinones
EA201990400A1 (en) COMPOUNDS AND COMPOSITIONS AND THEIR APPLICATION
EA201790949A1 (en) SUBSTITUTED 2,4-DIAMINOCHINOLINES AS NEW ANTI-CANCER FACILITIES
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
EA202090414A1 (en) COMPOUNDS AND THEIR APPLICATION
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202190588A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201790070A1 (en) BIPHENYLAMIDE CONTAINING MODIFIED SIMPLE ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 STIMULATORS
EA202191548A1 (en) HUMAN PLASMA CALLICREIN INHIBITORS
MX2019006863A (en) Heparanase inhibitors and use thereof.
EA202091003A1 (en) NEW PYRAZOLOPYROLOPYRIMIDINEDIONE DERIVATIVES AS P2X3 INHIBITORS
EA201791432A1 (en) COMPOSITIONS ON THE BASIS OF MONOMETHYLATE PREPARATION
EA202191115A1 (en) NEW PYRIDAZINES
EA201990947A1 (en) SUBSTITUTED DERIVATIVES 6- (1H-PYRAZOL-1-IL) PYRIMIDIN-4-AMINE AND THEIR APPLICATION
EA202191477A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201991835A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamides for the treatment of malignant neoplasms
EA202190766A1 (en) IMMUNOMODULATORS, THEIR COMPOSITIONS AND METHODS OF APPLICATION
EA201790795A1 (en) COMPOUNDS 4H-PYRIDO [1,2-a] PYRIMIDIN-4-IT
EA202091164A1 (en) COFFEE ACID DERIVATIVES AND THEIR APPLICATION